Literature DB >> 18515987

The local cytokine and chemokine milieu within malignant effusions.

Djordje Atanackovic1, Yanran Cao, Ji-Won Kim, Stephan Brandl, Ina Thom, Christiane Faltz, York Hildebrandt, Katrin Bartels, Andreas de Weerth, Susanna Hegewisch-Becker, Dieter Kurt Hossfeld, Carsten Bokemeyer.   

Abstract

BACKGROUND/AIMS: Malignant effusions offer a unique opportunity for the study of interactions between the human immune system and cancer. We have recently demonstrated that malignant effusions are characterized by an accumulation of T cells expressing chemokine receptors such as CCR4, which is commonly found on Th2 cells. In contrast, effector T cells expressing chemokine receptors typical for Th1 cells, such as CCR5, showed a diminished homing into malignant effusions.
METHODS: We analyzed concentrations of 12 different cytokines and 9 chemokines within malignant and nonmalignant effusions and investigated cytokine expression by effusion-infiltrating leukocytes.
RESULTS: We observed that concentrations of the immunoregulatory cytokine TGF-beta(1) and of angiogenic factors VEGF and IL-8 were markedly increased within effusions caused by malignancies. However, we did not observe signs of a typical Th1 or Th2 milieu. Analyzing concentrations of 9 different chemokines, we found elevated concentrations of the chemokines MDC, eotaxin, I-TAC, and MCP-1 in malignant effusions. Interestingly, tumor-infiltrating leukocytes themselves seemed to contribute strongly to the creation of a distinct cytokine/chemokine pattern within cancer-related effusions. Additional analyses suggested that this cytokine/chemokine milieu might support an enrichment of immunosuppressive leukocytes.
CONCLUSION: The local cytokine and chemokine milieu within malignant effusions seems to promote angiogenesis and to block an efficient immune-mediated antitumor response. An elimination of such tumor-promoting influences will be necessary in order to transform local immunotolerance into clinically relevant immune recognition of tumors causing malignant effusions. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18515987     DOI: 10.1159/000135689

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  11 in total

Review 1.  Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.

Authors:  Akshata Udyavar; Terrence L Geiger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-08-01       Impact factor: 4.291

2.  Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion: A meta-analysis.

Authors:  Yong-Chun Shen; Meng-Qi Liu; Chun Wan; Lei Chen; Tao Wang; Fu-Qiang Wen
Journal:  Exp Ther Med       Date:  2012-03-14       Impact factor: 2.447

3.  Evaluation of the phenotype pattern of macrophages isolated from malignant and non-malignant pleural effusions.

Authors:  Mariusz Kaczmarek; Agata Nowicka; Magdalena Kozłowska; Jakub Zurawski; Halina Batura-Gabryel; Jan Sikora
Journal:  Tumour Biol       Date:  2011-08-02

4.  Lung cancer cells induce senescence and apoptosis of pleural mesothelial cells via transforming growth factor-beta1.

Authors:  Zhi-Feng Miao; Wen-Ya Li; Zhen-Ning Wang; Ting-Ting Zhao; Ying-Ying Xu; Yong-Xi Song; Jin-Yu Huang; Hui-Mian Xu
Journal:  Tumour Biol       Date:  2014-11-30

5.  Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer.

Authors:  Anne-Marie Baird; Steven G Gray; Kenneth J O'Byrne
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

6.  Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands.

Authors:  K E Luker; J M Steele; L A Mihalko; P Ray; G D Luker
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

7.  Pleural Effusion IL-33/sST2 Levels and Effects of Low and High IL-33/sST2 Levels on Human Mesothelial Cell Adhesion and Migration.

Authors:  Ourania S Kotsiou; Rajesh M Jagirdar; Eleftherios D Papazoglou; Chrissi Hatzoglou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Inflammation       Date:  2019-12       Impact factor: 4.657

8.  Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.

Authors:  Arnaud Scherpereel; Bogdan Dragos Grigoriu; Marc Noppen; Thomas Gey; Bachar Chahine; Simon Baldacci; Jacques Trauet; Marie-Christine Copin; Jean-Paul Dessaint; Henri Porte; Myriam Labalette
Journal:  BMC Cancer       Date:  2013-07-02       Impact factor: 4.430

9.  Expression of YKL-40 and MIP-1a proteins in exudates and transudates: biomarkers for differential diagnosis of pleural effusions? A pilot study.

Authors:  Tonia Adamidi; Nikolaos Soulitzis; Eirini Neofytou; Savvas Zannetos; Andreas Georgiou; Kleomenis Benidis; Alexis Papadopoulos; Nikolaos M Siafakas; Sophia E Schiza
Journal:  BMC Pulm Med       Date:  2015-12-01       Impact factor: 3.317

10.  Enhanced Suppressive Activity of Regulatory T Cells in the Microenvironment of Malignant Pleural Effusions.

Authors:  Joanna Budna; Mariusz Kaczmarek; Agata Kolecka-Bednarczyk; Łukasz Spychalski; Piotr Zawierucha; Joanna Goździk-Spychalska; Michał Nowicki; Halina Batura-Gabryel; Jan Sikora
Journal:  J Immunol Res       Date:  2018-03-26       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.